Cardiovascular risk assessment in hypertensive patients: Beyond blood pressure measurements.

Daniela Lurati*

Anesthesiolog Department University Hospital Düsseldorf, Heinrich Heine University, Dusseldorf, Germany

Introduction

Hypertension, commonly known as high blood pressure, is a prevalent condition affecting millions of individuals worldwide. It is a major risk factor for cardiovascular diseases such as heart attacks, strokes, and heart failure. Traditionally, the management of hypertension has primarily focused on reducing blood pressure levels through lifestyle modifications and medication. However, recent research has highlighted the importance of a comprehensive cardiovascular risk assessment in hypertensive patients that goes beyond simple blood pressure measurements [1].

While blood pressure measurement remains a crucial component of hypertension management, it does not provide a complete picture of an individual's cardiovascular health. There are several additional factors that contribute to the overall risk profile of hypertensive patients. By assessing these factors, healthcare professionals can better understand the individual's risk of developing cardiovascular diseases and tailor their treatment strategies accordingly [2].

One such important aspect of cardiovascular risk assessment is evaluating the patient's lipid profile. Cholesterol levels, specifically low-density lipoprotein (LDL) cholesterol, play a significant role in the development of atherosclerosis, a condition characterized by the build-up of plaque in the arteries. Hypertensive patients often have dyslipidemia, with elevated LDL cholesterol levels. Assessing lipid profiles helps identify patients who may benefit from cholesterol-lowering medications, such as statins, in addition to blood pressure management. Another crucial parameter in cardiovascular risk assessment is blood glucose control. Hypertensive patients with poorly controlled diabetes are at a significantly higher risk of developing cardiovascular complications. Measuring fasting blood glucose levels and glycosylated hemoglobin (HbA1c) can provide valuable insights into an individual's diabetic status and guide appropriate interventions to optimize glycemic control [3].

Beyond blood pressure, lipid profile, and blood glucose, evaluating the patient's overall cardiovascular health is essential. This includes assessing their body mass index (BMI), waist circumference, and waist-to-hip ratio. Obesity and excessive abdominal fat deposition are closely linked to an increased risk of hypertension and cardiovascular diseases. A comprehensive risk assessment should also consider lifestyle factors such as smoking, physical activity levels, and dietary habits, as these have a significant impact on cardiovascular health. Furthermore, advanced diagnostic tests can offer valuable insights into an individual's cardiovascular risk profile. One such example is the measurement of high-sensitivity C-reactive protein (hsCRP), which is a marker of inflammation. Elevated levels of hsCRP are associated with an increased risk of cardiovascular events, and incorporating this test into risk assessments can aid in identifying high-risk hypertensive patients who may benefit from more aggressive treatment strategies [4].

In recent years, genetic testing has emerged as a powerful tool in cardiovascular risk assessment. Genetic variations can predispose individuals to hypertension and other cardiovascular conditions. Understanding an individual's genetic risk can help healthcare professionals personalize treatment plans, identify potential drug interactions, and predict the likelihood of treatment success. Genetic testing, when combined with traditional risk assessment tools, has the potential to revolutionize hypertension management and improve patient outcomes. It is important to note that cardiovascular risk assessment in hypertensive patients should be an ongoing process. Regular monitoring and reevaluation of risk factors allow healthcare professionals to adapt treatment strategies as needed. The goal is not only to lower blood pressure but also to address the underlying risk factors and improve overall cardiovascular health [5].

Conclusion

While blood pressure measurement remains a cornerstone in the management of hypertension, a comprehensive cardiovascular risk assessment goes beyond this single parameter. Assessing lipid profiles, blood glucose control, body composition, lifestyle factors, and incorporating advanced diagnostic tests and genetic testing can provide a more holistic view of a hypertensive patient's cardiovascular risk profile. By identifying and addressing these additional risk factors, healthcare professionals can optimize treatment strategies and significantly reduce the burden of cardiovascular diseases in hypertensive individuals.

References

1. Graue N, Körber A, Cesko E, et al. Malnutrition bei Patienten mit ulcus cruris. Hautarzt. 2008;3(59):212-9.

***Correspondence to:** Daniela Lurati, Anesthesiolog Department University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany, E-mail: daniela.lurati@med.uniduesseldorf.de

***Received:** 27-May-2023, Manuscript No. AAJHHC-23-103353; **Editor assigned:** 30-May-2023, PreQC No. AAJHHC-23-103353 (PQ); **Reviewed:** 06-Jun-2023, QC No. AAJHHC-23-103353; **Revised:** 19-Jun-2023, Manuscript No. AAJHHC-23-103353 (R); **Published:** 24-Jun-2023, DOI:10.35841/aajhhc-6.3.151*

***Citation:** Lurati D. Cardiovascular risk assessment in hypertensive patients: Beyond blood pressure measurements. J Hypertens Heart Care.2023;6(3):151*

2. Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: Results from the China hypertension survey, 2012–2015. Circ. 2018;137(22):2344-56.

3. Clark M, Tilman D. Comparative analysis of environmental impacts of agricultural production systems, agricultural input efficiency, and food choice. Environ Res Lett. 2017;12(6):064016.

4. Wakkers PM, Hellendoorn HB, De Weegh GO, et al. Applications of statistics in clinical chemistry: A critical evaluation of regression lines. Clin Chim Acta. 1975;64(2):173-84.

5. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148(1):16-29.

Citation: *Lurati D. Cardiovascular risk assessment in hypertensive patients: Beyond blood pressure measurements. J Hypertens Heart Care.2023;6(3):151*